PR Newswire Asia's news > Medical/Pharmaceuticals

 < Previous page   |   Title only   |   Print    Next page > 
     
A Formidable Type of Childhood Cancer Gets Added to Highly Regarded Library of Treatment Recommendations
New NCCN Guidelines for Pediatric Bone Sarcoma focus on how to provide the best care possible for children and adolescents with Ewing sarcoma. ...
2026-10-01T    Books   Education   Health Care/Hospital   Medical/Pharmaceuticals 
Bambusa Therapeutics Initiates Subcutaneous Dosing of BBT001 in Atopic Dermatitis, Following Compelling Intravenous Proof-of-Concept Data
First patient dosed as Bambusa expands global development of its long-acting bispecific antibody targeting both IL-4Rα and IL-31 ...
2026-10-01T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Advances in Digital Therapeutics and HoneyNaps AI Enhance Clinical Trial Efficiency
Supporting pharmaceutical, medical device, wellness, and research organizations in obtaining standardized sleep data Expanding the use of SOMNUM scoring technology to provide clinical analysis services ...
2026-10-01T    Health Care/Hospital   Medical Equipment   Medical/Pharmaceuticals 
Emerald Clinical Trials Appoints Michael Stibilj as Chief Executive Officer to Lead Next Phase of Global Growth
SINGAPORE , Oct. 1, 2026 /PRNewswire/ -- Emerald  Clinical Trials , a leading global clinical research organization anchored in Asia-Pacific, today announced the appointment of Michael Stibilj ...
2026-10-01T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Piramal Pharma Solutions and NP2 to Complete Cyclophosphamide Development Phase Next Month
Piramal and NP2 are set to complete the drug development phase of the generic cancer drug cyclophosphamide this October. The development and manufacturing activities are being conducted at Piramal's ...
2026-09-30T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Phrontline Biopharma Doses First Patient in Global Phase I/II Trial of TJ102, an FRα × CDH6 Bispecific Dual-Payload ADC
First clinical program built on Phrontline's DLP1 branched dual-payload linker platform ...
2026-09-30T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
The 94th CMEF, the World's Leading Medical Device Industry Event, Set to Open in Beijing Oct. 21-24
BEIJING , Sept. 30, 2026 /PRNewswire/ -- The 94th China International Medical Equipment Fair (CMEF) and concurrent events—including ICMD, covering medical device design and manufacturing; CRS, focusing ...
2026-09-30T    Biotechnology   Health Care/Hospital   Medical Equipment   Medical/Pharmaceuticals 
Zhendong Pharmaceutical Announces Publication of Phase IIb Study of Investigational Vaginal Lactobacillus Capsule in the National Medical Journal of China
BEIJING , Sept. 30, 2026 /PRNewswire/ -- Zhendong Pharmaceutical announced that results from a multicenter, randomized, double-blind, placebo-controlled Phase IIb study evaluating its investigational ...
2026-09-30T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Zhendong Pharmaceutical Announces Publication of Phase IIb Study of Investigational Vaginal Lactobacillus Capsule in the National Medical Journal of China
BEIJING , Sept. 30, 2026 /PRNewswire/ -- Zhendong Pharmaceutical announced that results from a multicenter, randomized, double-blind, placebo-controlled Phase IIb study evaluating its investigational ...
2026-09-30T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
EASD 2026 | Ecnoglutide Demonstrates Favorable Safety Profile in Adolescents with Obesity
HANGZHOU, China , Sept. 30, 2026 /PRNewswire/ -- At the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD), Hangzhou Sciwind Biosciences Co., Ltd. ("Sciwind") ...
2026-09-30T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
 < Previous page    Next page >

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2026 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.